Meeting
2020 ASCO Virtual Scientific Program
Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP).
Authors
Nitin Jain
The University of Texas MD Anderson Cancer Center, Houston, TX
Nitin Jain , Abhishek Maiti , Farhad Ravandi , Marina Konopleva , Yesid Alvarado , Tapan M. Kadia , Nicholas James Short , Gautam Borthakur , Kiran Naqvi , Naveen Pemmaraju , Courtney Denton Dinardo , Naval Guastad Daver , Musa Yilmaz , Keyur P. Patel , Debra B Linderman , Rebecca Garris , Elias Jabbour , Jorge E. Cortes , Hagop M. Kantarjian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT02311998
Citation
J Clin Oncol 38: 2020 (suppl; abstr 7512)
DOI
10.1200/JCO.2020.38.15_suppl.7512
Abstract #
7512
Poster Bd #
285
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome–positive (Ph+) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).
First Author: Wendy Stock
Poster
2016 ASCO Annual Meeting
Phase I study of BP1001 (Liposomal Grb2 Antisense) in patients with hematologic malignancies.
First Author: Maro Ohanian
Poster
2023 ASCO Annual Meeting
Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.
First Author: Brian Ko
Poster
2023 ASCO Annual Meeting
Report of a chronic myeloid leukemia registry in a low-and middle-income setting.
First Author: Nicolas Anthony Othieno-Abinya